{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:41:41Z","timestamp":1777477301619,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T00:00:00Z","timestamp":1523491200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13063-018-2613-8","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T13:12:50Z","timestamp":1523538770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2288-7461","authenticated-orcid":false,"given":"Guillaume","family":"Mouillet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Justine","family":"Paillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan","family":"Maurina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dewi","family":"Vernerey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Nguyen Tan Hon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamadi","family":"Almotlak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Calcagno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Berthod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Robert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelia","family":"Meurisse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Thiery-Vuillemin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,12]]},"reference":[{"key":"2613_CR1","volume-title":"European public assessment report (EPAR) for Sutent","author":"European Medicines Agency","year":"2014","unstructured":"European Medicines Agency. European public assessment report (EPAR) for Sutent. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000687\/WC500057689.pdf . Accessed 3 Jan 2018."},{"key":"2613_CR2","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","volume":"66","author":"BE Houk","year":"2010","unstructured":"Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2010;66:357\u201371.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2613_CR3","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/S1470-2045(13)70464-9","volume":"14","author":"BI Rini","year":"2013","unstructured":"Rini BI, Melichar B, Ueda T, Gr\u00fcnwald V, Fishman MN, Arranz JA, et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol. 2013;14:1233\u201342.","journal-title":"Lancet Oncol"},{"key":"2613_CR4","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00280-014-2435-7","volume":"73","author":"A Thiery-Vuillemin","year":"2014","unstructured":"Thiery-Vuillemin A, Mouillet G, Nguyen Tan Hon T, Montcuquet P, Maurina T, Almotlak H, et al. Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol. 2014;73:999\u20131007.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2613_CR5","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.ejca.2014.01.025","volume":"50","author":"YG Najjar","year":"2014","unstructured":"Najjar YG, Mittal K, Elson P, Wood L, Garcia JA, Dreicer R, et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Can. 2014;50:1084\u20139.","journal-title":"Eur J Can"},{"key":"2613_CR6","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.1200\/JCO.2017.35.6_suppl.533","volume":"35","author":"E Jonasch","year":"2017","unstructured":"Jonasch E, Slack R, Geynisman DM, Milowsky MI, Rathmell K, Stovall S, et al. Phase II study of alternate sunitinib schedule in patients with metastatic renal cell carcinoma. J Clin Oncol. 2017;35:4513.","journal-title":"J Clin Oncol"},{"key":"2613_CR7","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1200\/JCO.2017.35.15_suppl.4514","volume":"35","author":"GA Bjarnason","year":"2017","unstructured":"Bjarnason GA, Knox JJ, Kollmannsberger CK, Soulieres D, Ernst DS, Zalewski P, et al. Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer. J Clin Oncol. 2017;35:4514.","journal-title":"J Clin Oncol"},{"key":"2613_CR8","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1093\/annonc\/mdv357","volume":"26","author":"JL Lee","year":"2015","unstructured":"Lee JL, Kim MK, Park I, Ahn J-H, Lee DH, Ryoo HM, et al. RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial. Ann Oncol. 2015;26:2300\u20135.","journal-title":"Ann Oncol"},{"key":"2613_CR9","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1093\/annonc\/mdv315","volume":"26","author":"S Bracarda","year":"2015","unstructured":"Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, et al. Sunitinib administered on 2\/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol. 2015;26:2107\u201313.","journal-title":"Ann Oncol"},{"key":"2613_CR10","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/annonc\/mdv030","volume":"26","author":"S Kalra","year":"2015","unstructured":"Kalra S, Rini BI, Jonasch E. Alternate sunitinib schedules in patients with metastatic renal cell carcinoma. Ann Oncol. 2015;26:1300\u20134.","journal-title":"Ann Oncol"},{"key":"2613_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"2613_CR12","unstructured":"European Medicines Agency. Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000687\/WC500057737.pdf . Accessed 3 Jan 2018."},{"key":"2613_CR13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365\u201376.","journal-title":"J Natl Cancer Inst"},{"key":"2613_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy Amst Neth. 1990;16:199\u2013208.","journal-title":"Health Policy Amst Neth"},{"key":"2613_CR15","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722\u201331.","journal-title":"N Engl J Med"},{"key":"2613_CR16","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1016\/j.clgc.2016.08.022","volume":"15","author":"N Marschner","year":"2017","unstructured":"Marschner N, Staehler M, M\u00fcller L, Nusch A, Harde J, Koska M, et al. Survival of patients with advanced or metastatic renal cell carcinoma in routine practice differs from that in clinical trials\u2014analyses from the German Clinical RCC Registry. Clin Genitourin Cancer. 2017;15:e209\u201315.","journal-title":"Clin Genitourin Cancer"},{"key":"2613_CR17","volume-title":"FDA approves sunitinib malate for adjuvant treatment of renal cell carcinoma","author":"U.S. Food and Drug Administration","year":"2017","unstructured":"U.S. Food and Drug Administration. FDA approves sunitinib malate for adjuvant treatment of renal cell carcinoma. 2017. https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm585686.htm . Accessed 3 Jan 2018."},{"key":"2613_CR18","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","volume":"375","author":"A Ravaud","year":"2016","unstructured":"Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375:2246\u201354.","journal-title":"N Engl J Med"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2613-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-2613-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2613-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T16:08:58Z","timestamp":1604160538000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-2613-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,12]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2613"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-2613-8","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,12]]},"assertion":[{"value":"17 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial was reviewed and approved by the ethics committee of the University Hospital of Besan\u00e7on and is registered with the Clinical Trials Registry (ClinicalTrials.gov identifier: NCT02689167). All participants will provide written informed consent in accordance with the Declaration of Helsinki. The review boards at all participating institutions will approve the study, which is conducted according to the Good Clinical Practice guidelines of the International Conference on Harmonisation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Thiery-Vuillemin Antoine and Dr. Mouillet Guillaume received honoraria from Novartis, Pfizer, Roche, BMS, and Ipsen. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"221"}}